Patent Infringement: GSK moves court against Glenmark over Vilor F
New Delhi: Coming down on Glenmark Pharmaceuticals, British drug maker GlaxoSmithKline has filed a patent infringement case in the Delhi High Court against the drug maker for allegedly infringing on GSK's Indian patent for Vilanterol, an active ingredient.
It has been alleged that Glenmark's Vilor F medication infringes on GSK's vilanterol patent in India.
Vilanterol is a long-acting beta2-adrenergic agonist being jointly developed by GlaxoSmithKline (GSK) and Theravance (now Innoviva) and is used in combination with other bronchodilators for the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Upon administration, vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.